<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690950</url>
  </required_header>
  <id_info>
    <org_study_id>110895</org_study_id>
    <nct_id>NCT00690950</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart</brief_title>
  <official_title>Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urologic Consultants of Southeastern PA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urologic Consultants of Southeastern PA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume,
      improving symptoms based on International Prostate Symptom score,and lower pvr based on the
      scientific information that dutasteride inhibits both Type I and II 5-alpha-reducatase vs.
      finasteride which only inhibits the Type II enzyme
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory parameters: including serum testosterone, DHT level and PSA</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>volume measurements of TRUSP and PVR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A decrease in the AUASI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>0.5mg capsule, taken once daily for 12 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age 50-80

          -  On finasteride for no less than 12 months

          -  Willing to undergo all necessary test in the 12 month evaluation

        Exclusion Criteria:

          -  History of medication non-compliance

          -  Unwillingness to undergo/tolerate 2 blood draws

          -  Unwillingness to tolerate/undergo 2 TRUSP
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urologic Consultants of Southeastern PA</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.urologicconsultsepa.com</url>
  </link>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>June 4, 2008</last_update_submitted>
  <last_update_submitted_qc>June 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Richard C. Harkaway</name_title>
    <organization>Urologic consultants of Southeastern PA</organization>
  </responsible_party>
  <keyword>BPH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

